Biomarkers as therapy monitoring for postmenopausal osteoporosis: a systematic review.

Biomarkers / blood Bone Density / drug effects Bone Remodeling / drug effects Female Humans Osteoporosis, Postmenopausal / blood Randomized Controlled Trials as Topic
Biomarkers Osteoporosis Postmenopausal Therapy monitoring

Journal

Journal of orthopaedic surgery and research
ISSN: 1749-799X
Titre abrégé: J Orthop Surg Res
Pays: England
ID NLM: 101265112

Informations de publication

Date de publication:
18 May 2021
Historique:
received: 21 04 2021
accepted: 06 05 2021
entrez: 19 5 2021
pubmed: 20 5 2021
medline: 6 10 2021
Statut: epublish

Résumé

Biochemical markers of bone turnover (BTMs), such as bone alkaline phosphatase (bALP), procollagen type I N propeptide (PINP), serum cross-linked C-telopeptides of type I collagen (bCTx), and urinary cross-linked N-telopeptides of type I collagen (NTx), are commonly used for therapy monitoring purposes for osteoporotic patients. The present study evaluated the potential role of BTMs as therapy monitoring. All randomized clinical trials (RCTs) comparing two or more pharmacological treatments for postmenopausal osteoporosis were accessed. Only studies that reported the value of bALP, PINP, bCTx, and NTx at last follow-up were included. A multivariate analysis was performed to assess associations between these biomarkers and clinical outcomes and rate of adverse events in patients with postmenopausal osteoporosis. A multiple linear model regression analysis through the Pearson product-moment correlation coefficient was used. A total of 16 RCTs (14,446 patients) were included. The median age was 67 years, and the median BMI 25.4 kg/m Our analysis supports the adoption of BTMs in therapy monitoring of osteoporotic patients. Level I, systematic review of RCTs.

Sections du résumé

BACKGROUND BACKGROUND
Biochemical markers of bone turnover (BTMs), such as bone alkaline phosphatase (bALP), procollagen type I N propeptide (PINP), serum cross-linked C-telopeptides of type I collagen (bCTx), and urinary cross-linked N-telopeptides of type I collagen (NTx), are commonly used for therapy monitoring purposes for osteoporotic patients. The present study evaluated the potential role of BTMs as therapy monitoring.
METHODS METHODS
All randomized clinical trials (RCTs) comparing two or more pharmacological treatments for postmenopausal osteoporosis were accessed. Only studies that reported the value of bALP, PINP, bCTx, and NTx at last follow-up were included. A multivariate analysis was performed to assess associations between these biomarkers and clinical outcomes and rate of adverse events in patients with postmenopausal osteoporosis. A multiple linear model regression analysis through the Pearson product-moment correlation coefficient was used.
RESULTS RESULTS
A total of 16 RCTs (14,446 patients) were included. The median age was 67 years, and the median BMI 25.4 kg/m
CONCLUSION CONCLUSIONS
Our analysis supports the adoption of BTMs in therapy monitoring of osteoporotic patients.
LEVEL OF EVIDENCE METHODS
Level I, systematic review of RCTs.

Identifiants

DOI: 10.1186/s13018-021-02474-7 PMID: 34006294 PMC: PMC8130375
pubmed: 34006294
doi: 10.1186/s13018-021-02474-7
pii: 10.1186/s13018-021-02474-7
pmc: PMC8130375
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

318

Références

Clin Chem. 1997 Sep;43(9):1570-6
pubmed: 9299935
J Orthop Surg Res. 2019 Feb 28;14(1):68
pubmed: 30819222
J Intern Med. 2019 Apr;285(4):381-394
pubmed: 30657216
Curr Opin Endocrinol Diabetes Obes. 2018 Dec;25(6):366-372
pubmed: 30299435
Bone. 1988;9(1):67-9
pubmed: 3377921
J Bone Miner Res. 1996 Oct;11(10):1531-8
pubmed: 8889854
J Clin Endocrinol Metab. 1998 Jan;83(1):68-75
pubmed: 9435418
Br J Orthod. 1998 May;25(2):101-7
pubmed: 9668992
J Bone Miner Res. 1998 Nov;13(11):1747-54
pubmed: 9797484
Orthop Surg. 2017 Feb;9(1):103-109
pubmed: 28276638
Bone. 2014 Apr;61:27-32
pubmed: 24389416
Adv Ther. 2010 May;27(5):314-20
pubmed: 20526703
Calcif Tissue Int. 1998 Nov;63(5):369-74
pubmed: 9799819
Yonsei Med J. 2008 Feb 29;49(1):119-28
pubmed: 18306478
Br J Cancer. 2000 Feb;82(4):858-64
pubmed: 10732759
Osteoporos Int. 2000;11 Suppl 6:S30-44
pubmed: 11193238
J Bone Miner Res. 2009 Dec;24(12):2032-8
pubmed: 19453262
Bone. 2014 Jan;58:48-54
pubmed: 24141036
J Bone Miner Res. 2003 Jun;18(6):1051-6
pubmed: 12817758
Lancet Diabetes Endocrinol. 2017 Nov;5(11):908-923
pubmed: 28689768
Biomark Med. 2008 Oct;2(5):495-508
pubmed: 20477426
J Bone Miner Res. 2004 Mar;19(3):394-401
pubmed: 15040827
J Bone Miner Res. 2016 Feb;31(2):274-80
pubmed: 26241926
Osteoporos Int. 2011 Feb;22(2):391-420
pubmed: 21184054
J Clin Endocrinol Metab. 2002 Aug;87(8):3609-17
pubmed: 12161484
Osteoporos Int. 1999;10(5):399-407
pubmed: 10591838
JAMA. 1999 Oct 13;282(14):1344-52
pubmed: 10527181
Clin Biochem. 1997 Dec;30(8):573-93
pubmed: 9455610
Osteoporos Int. 2014 Jul;25(7):1953-61
pubmed: 24676847
Adv Ther. 2019 Oct;36(10):2811-2824
pubmed: 31440982
Osteoporos Int. 2009 Jun;20(6):843-51
pubmed: 19190842
Clin Chem. 2000 Mar;46(3):431
pubmed: 10702538
Calcif Tissue Int. 2009 Nov;85(5):389-97
pubmed: 19816648
J Bone Miner Res. 1987 Dec;2(6):595-610
pubmed: 3455637
Clin Chem. 2017 Feb;63(2):464-474
pubmed: 27940448
Osteoporos Int. 2001;12(11):922-30
pubmed: 11808544
Breast Cancer Res Treat. 2020 Feb;180(1):187-195
pubmed: 31912328
Ann Clin Biochem. 2014 Mar;51(Pt 2):189-202
pubmed: 24399365
J Bone Miner Res. 2012 Jan;27(1):195-201
pubmed: 21956772
Climacteric. 2005 Sep;8(3):251-62
pubmed: 16390757
J Clin Endocrinol Metab. 1993 Oct;77(4):1046-53
pubmed: 8104954
J Bone Miner Res. 2004 Aug;19(8):1250-8
pubmed: 15231011
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
J Lab Clin Med. 1996 Jan;127(1):67-70
pubmed: 8592098
J Clin Endocrinol Metab. 1984 Jan;58(1):110-20
pubmed: 6227628
Endocr Res. 2002 Aug;28(3):257-64
pubmed: 12489574
J Clin Endocrinol Metab. 1997 Jan;82(1):265-74
pubmed: 8989272
J Clin Endocrinol Metab. 2012 Jan;97(1):286-92
pubmed: 22072741
J Clin Endocrinol Metab. 2014 May;99(5):1694-700
pubmed: 24517156
Eur J Endocrinol. 2018 Jan;178(1):R19-R31
pubmed: 29046326
Osteoporos Int. 2014 Dec;25(12):2729-41
pubmed: 25074351
Biomed Res Int. 2015;2015:421746
pubmed: 26247020
Osteoporos Int. 1999;10(4):307-11
pubmed: 10692980
Osteoporos Int. 2000;11 Suppl 6:S2-17
pubmed: 11193237
Clin Biochem Rev. 2005 Nov;26(4):97-122
pubmed: 16648882
Osteoporos Int. 2011 Oct;22(10):2735-42
pubmed: 21104227
J Bone Miner Res. 2002 May;17(5):826-33
pubmed: 12009013
J Bone Miner Metab. 2010 Mar;28(2):233-9
pubmed: 19806302

Auteurs

Filippo Migliorini (F)

Department of Orthopaedics, University Clinic Aachen, RWTH Aachen University Clinic, Pauwelsstraße 30, 52074, Aachen, Germany. migliorini.md@gmail.com.
ORCID: 0000-0001-7220-1221

Nicola Maffulli (N)

Department of Medicine, Surgery and Dentistry, University of Salerno, Via S. Allende, 84081, Baronissi, SA, Italy.
School of Pharmacy and Bioengineering, Keele University Faculty of Medicine, Thornburrow Drive, Stoke on Trent, England.
Centre for Sports and Exercise Medicine, Mile End Hospital, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, 275 Bancroft Road, London, E1 4DG, England.

Filippo Spiezia (F)

Department of Orthopedics and Trauma Surgery, Ospedale San Carlo Potenza, Via Potito Petrone, Potenza, Italy.

Markus Tingart (M)

Department of Orthopaedics, University Clinic Aachen, RWTH Aachen University Clinic, Pauwelsstraße 30, 52074, Aachen, Germany.

Peretti Giuseppe Maria (PG)

Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.
Orthopedics and Traumatology, University of Milan, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy.

Giorgino Riccardo (G)

Orthopedics and Traumatology, University of Milan, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Biomarkers as therapy monitoring for...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système locomoteur › Densité osseuse › Biomarkers as therapy monitoring for...
questionsmedicales.fr › Phénomènes biologiques › Régénération › Remodelage osseux › Biomarkers as therapy monitoring for...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Biomarkers as therapy monitoring for...
questionsmedicales.fr › Maladies métaboliques et nutritionnelles › Maladies métaboliques › Maladies osseuses métaboliques › Ostéoporose › Ostéoporose post-ménopausique › Biomarkers as therapy monitoring for...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Essais cliniques comme sujet › Essais cliniques contrôlés comme sujet › Essais contrôlés randomisés comme sujet › Biomarkers as therapy monitoring for...